Literature DB >> 24565839

p53 down-regulates SETDB1 gene expression during paclitaxel induced-cell death.

Hee-Jung Noh1, Kyeong-Ah Kim1, Keun-Cheol Kim2.   

Abstract

Paclitaxel (PTX) is a chemotherapeutic drug which induces tubulin stability and regulates expression of death related genes in human cancer cells. Its anticancer mechanism is well known, however its effects on chromatin remodeling factors are poorly understood. In this study, we examine if PTX affects expression of SETDB1 HMTase during cell death. PTX induces cell death via G2/M arrest in human lung cancer cells. PTX treatment induces the p53 protein, but down-regulates expression of SETDB1 at the transcriptional level as well as the protein level. SETDB1 promoter activity is increased to approximately 30-fold in normal condition, but the activity is significantly inhibited in the PTX treated group. In addition, p53 transfection inhibits SETDB1 promoter activity. The p53 protein directly binds to proximal region of the SETDB1 promoter, and H3K9me3 occupancy in this region also increased in the presence of p53. Immunoprecipitation experiment showed interaction of p53 and SUV39H1, suggesting that association of p53 and SUV39H1 is responsible for increased H3K9me3 occupancy and transcription repression of SETDB1. This result demonstrates that PTX down-regulates SETDB1 gene expression in a p53 dependent manner, and p53 might participate in heterochromatic repression on the promoter regions of SETDB1.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  H3K9me3; Paclitaxel; SETDB1; SUV39H1; p53

Mesh:

Substances:

Year:  2014        PMID: 24565839     DOI: 10.1016/j.bbrc.2014.02.053

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  A drive in SUVs: From development to disease.

Authors:  Vinay Kumar Rao; Ananya Pal; Reshma Taneja
Journal:  Epigenetics       Date:  2017-01-20       Impact factor: 4.528

2.  Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.

Authors:  A Lafuente-Sanchis; Á Zúñiga; J M Galbis; A Cremades; M Estors; N J Martínez-Hernández; J Carretero
Journal:  Clin Transl Oncol       Date:  2015-11-05       Impact factor: 3.405

Review 3.  Potential anti-cancer activities and mechanisms of costunolide and dehydrocostuslactone.

Authors:  Xuejing Lin; Zhangxiao Peng; Changqing Su
Journal:  Int J Mol Sci       Date:  2015-05-13       Impact factor: 5.923

4.  Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.

Authors:  Qi Fei; Ke Shang; Jianhua Zhang; Shannon Chuai; Desheng Kong; Tianlun Zhou; Shijun Fu; Ying Liang; Chong Li; Zhi Chen; Yuan Zhao; Zhengtian Yu; Zheng Huang; Min Hu; Haiyan Ying; Zhui Chen; Yun Zhang; Feng Xing; Jidong Zhu; Haiyan Xu; Kehao Zhao; Chris Lu; Peter Atadja; Zhi-Xiong Xiao; En Li; Jianyong Shou
Journal:  Nat Commun       Date:  2015-10-16       Impact factor: 14.919

5.  Volatile oil from Saussurea lappa exerts antitumor efficacy by inhibiting epithelial growth factor receptor tyrosine kinase-mediated signaling pathway in hepatocellular carcinoma.

Authors:  Xuejing Lin; Zhangxiao Peng; Xiaohui Fu; Chunying Liu; Yang Xu; Weidan Ji; Jianhui Fan; Lei Chen; Lin Fang; Yao Huang; Changqing Su
Journal:  Oncotarget       Date:  2016-11-29

6.  Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.

Authors:  Paola Cruz-Tapias; Vlada Zakharova; Oscar M Perez-Fernandez; William Mantilla; Sandra RamÍRez-Clavijo; Slimane Ait-Si-Ali
Journal:  Cancers (Basel)       Date:  2019-08-08       Impact factor: 6.639

Review 7.  SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis.

Authors:  Jacob Batham; Pek Siew Lim; Sudha Rao
Journal:  Cancers (Basel)       Date:  2019-08-09       Impact factor: 6.639

8.  Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells.

Authors:  Jin-Ah Park; Han-Heom Na; Hyeon-Ok Jin; Keun-Cheol Kim
Journal:  Mol Cells       Date:  2019-12-31       Impact factor: 5.034

Review 9.  SETDB1 in cancer: overexpression and its therapeutic implications.

Authors:  Vanessa J Lazaro-Camp; Kiarash Salari; Xiangbing Meng; Shujie Yang
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

10.  SETDB1 mediated FosB expression increases the cell proliferation rate during anticancer drug therapy.

Authors:  Han-Heom Na; Hee-Jung Noh; Hyang-Min Cheong; Yoonsung Kang; Keun-Cheol Kim
Journal:  BMB Rep       Date:  2016-04       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.